Publications by authors named "T Takai"
Seizure is among the most severe FDA black box warnings of neurotoxicity reported on drug labels. Gaining a better mechanistic understanding of off-targets causative of seizure will improve identification of potential seizure risks preclinically. In the present study, we evaluated an in vitro panel of 9 investigational (Cav2.
View Article and Find Full Text PDFBackground: Androgen-receptor signaling inhibitors (ARSIs) become the new standard of care for metastatic hormone-sensitive prostate cancer (mHSPC). It is unknown whether time to castration resistance (TTCR), when using the first-line ARSIs, offers predictive value in mHSPC. We sought to assess the clinical outcomes for mHSPC patients treated with first-line ARSIs focusing on the TTCR.
View Article and Find Full Text PDFArticle Synopsis
- Current treatments for advanced prostate cancer mainly focus on androgen receptor pathways, but issues like castration-resistant prostate cancer (CRPC) pose significant challenges.
- The study introduces BSJ-5-63, a new triple degrader that targets specific cyclin-dependent kinases (CDK12, CDK7, CDK9) to reduce both DNA repair genes and androgen receptor signaling, enhancing treatment efficacy.
- BSJ-5-63 creates a lasting "BRCAness" state, allowing for effective sequential therapy with PARP inhibitors while reducing drug-related side effects and resistance, potentially benefiting a wide range of CRPC patients.